[go: up one dir, main page]

WO1999041369A3 - Genetic vaccine vector engineering - Google Patents

Genetic vaccine vector engineering Download PDF

Info

Publication number
WO1999041369A3
WO1999041369A3 PCT/US1999/003022 US9903022W WO9941369A3 WO 1999041369 A3 WO1999041369 A3 WO 1999041369A3 US 9903022 W US9903022 W US 9903022W WO 9941369 A3 WO9941369 A3 WO 9941369A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine vector
genetic vaccine
methods
vector engineering
cell
Prior art date
Application number
PCT/US1999/003022
Other languages
French (fr)
Other versions
WO1999041369A2 (en
Inventor
Juha Punnonen
Willem P C Stemmer
Robert Gerald Whalen
Russell Howard
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Priority to MXPA00007891A priority Critical patent/MXPA00007891A/en
Priority to CA002320626A priority patent/CA2320626A1/en
Priority to AU32910/99A priority patent/AU3291099A/en
Priority to JP2000531550A priority patent/JP2002503461A/en
Priority to EP99932508A priority patent/EP1056842A2/en
Publication of WO1999041369A2 publication Critical patent/WO1999041369A2/en
Publication of WO1999041369A3 publication Critical patent/WO1999041369A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention provides methods of obtaining genetic vaccines by use of DNA shuffling. Through use of the claimed methods, vectors can be obtained which exhibit efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.
PCT/US1999/003022 1998-02-11 1999-02-10 Genetic vaccine vector engineering WO1999041369A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA00007891A MXPA00007891A (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering.
CA002320626A CA2320626A1 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering
AU32910/99A AU3291099A (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering
JP2000531550A JP2002503461A (en) 1998-02-11 1999-02-10 Gene vaccine vector engineering
EP99932508A EP1056842A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2176998A 1998-02-11 1998-02-11
US7429498P 1998-02-11 1998-02-11
US09/021,769 1998-02-11
US60/074,294 1998-02-11

Publications (2)

Publication Number Publication Date
WO1999041369A2 WO1999041369A2 (en) 1999-08-19
WO1999041369A3 true WO1999041369A3 (en) 1999-09-23

Family

ID=26695070

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/003020 WO1999041368A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
PCT/US1999/003022 WO1999041369A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering
PCT/US1999/003023 WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003020 WO1999041368A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003023 WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors

Country Status (6)

Country Link
EP (3) EP1056842A2 (en)
JP (3) JP2002503478A (en)
AU (3) AU2674299A (en)
CA (3) CA2320626A1 (en)
MX (3) MXPA00007891A (en)
WO (3) WO1999041368A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US7579146B2 (en) 1999-01-05 2009-08-25 Trustees Of Boston University Nucleic acid cloning
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
WO1999023107A1 (en) 1997-10-31 1999-05-14 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
IL140125A0 (en) 1998-06-17 2002-02-10 Maxygen Inc Method for producing polynucleotides with desired properties
US6605430B1 (en) 1998-08-12 2003-08-12 Maxygen, Inc. DNA shuffling of monooxygenase genes for production of industrial chemicals
AU6510799A (en) 1998-10-07 2000-04-26 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
MXPA00009723A (en) * 1999-02-04 2003-09-22 Diversa Corp Non-stochastic generation of genetic vaccines and enzymes.
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
EP1206526A2 (en) 1999-07-22 2002-05-22 The Procter & Gamble Company Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
MXPA02000840A (en) 1999-07-22 2002-07-30 Procter & Gamble Subtilisin protease variants having amino acid substitutions in defined epitope regions.
EP1196548A2 (en) 1999-07-22 2002-04-17 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
AU2001234980A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Methods of preparing and using a viral vector library
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
AU5995701A (en) * 2000-05-26 2001-12-03 Univ Australian Synthetic peptides and uses therefore
WO2002000897A2 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel chimeric promoters
US7094875B2 (en) 2000-06-23 2006-08-22 Maxygen, Inc. Co-stimulatory polypeptides
EP1299115A2 (en) * 2000-06-26 2003-04-09 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
DE10060959A1 (en) * 2000-12-06 2002-06-20 Aventis Res & Tech Gmbh & Co Processes for isolating and identifying effectors
CA2436214C (en) * 2001-02-02 2012-12-04 Large Scale Biology Corporation A method of increasing complementarity in a heteroduplex polynucleotide
US6723537B2 (en) 2001-05-18 2004-04-20 Rigel Pharmaceuticals, Incorporated Directed evolution of protein in mammalian cells
AU2002326437A1 (en) * 2001-07-19 2003-03-03 Icogen Corporation Methods for the identification of peptidyl compounds interacting with extracellular target molecules
US7544669B2 (en) * 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
CA2481479C (en) 2002-02-26 2012-12-11 Maxygen, Inc. Novel flavivirus antigens
EP1493027B1 (en) 2002-03-01 2014-10-15 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional bio-molecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
AU2003243157C1 (en) 2002-04-19 2008-09-04 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1576151A4 (en) 2002-08-06 2006-05-17 Verdia Inc VARIANTS OF AMINE OXIDASE AP1
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
EP2194133B1 (en) 2003-03-06 2015-12-02 BASF Enzymes LLC Amylases, nucleic acids encoding them and methods for making and using them
US8298799B2 (en) 2003-03-07 2012-10-30 Dsm Ip Assets B. V. Hydrolases, nucleic acids encoding them and methods for making and using them
ES2545639T3 (en) 2003-04-04 2015-09-14 Basf Enzymes Llc Pectate liases, nucleic acids that encode them and methods for their preparation and use
EP2535414B1 (en) 2003-04-29 2017-12-13 Pioneer Hi-Bred International Inc. Novel glyphosate-n-acetyltransferase (gat) genes
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CN101370819A (en) 2003-07-02 2009-02-18 维莱尼姆公司 Glucanases, nucleic acids encoding them and methods of making and using them
WO2005021714A2 (en) 2003-08-11 2005-03-10 Diversa Corporation Laccases, nucleic acids encoding them and methods for making and using them
WO2005123929A2 (en) 2004-06-09 2005-12-29 Pioneer Hi-Bred International, Inc. Plastid transit peptides
EP2468853B1 (en) 2004-06-16 2015-04-01 DSM IP Assets B.V. Method for enzymatic decolorization of pheophytin
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
NZ583532A (en) 2005-03-15 2011-09-30 Verenium Corp Cellulases, nucleic acids encoding them and methods for making and using them
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
WO2007092314A2 (en) 2006-02-02 2007-08-16 Verenium Corporation Esterases and related nucleic acids and methods
EP2444488B1 (en) 2006-02-10 2014-02-12 Verenium Corporation Cellucloytic enzymes, nucleic acids encoding them and methods for making and using them
EP3406621A1 (en) 2006-02-14 2018-11-28 BP Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
EA019971B1 (en) 2006-03-07 2014-07-30 Верениум Корпорейшн Aldolases, nucleic acids encoding them and methods for making and using them
EP2322643B1 (en) 2006-03-07 2014-07-09 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EP2444413A1 (en) 2006-08-04 2012-04-25 Verenium Corporation Methods for oil or gas well drilling, washing and/or fracturing
EP2617820B1 (en) 2006-09-21 2016-03-23 BASF Enzymes LLC Phytases, nucleic acids encoding them and methods for making and using them
WO2008036863A2 (en) 2006-09-21 2008-03-27 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
MX2009006782A (en) 2006-12-21 2009-09-21 Verenium Corp Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them.
AU2008210495B2 (en) 2007-01-30 2014-02-27 Bp Corporation North America, Inc. Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
DK2708602T3 (en) 2007-10-03 2019-06-03 Bp Corp North America Inc Xylanases, nucleic acids encoding them and methods of making and using them
PL2222697T3 (en) 2007-11-01 2013-05-31 Astellas Pharma Inc Immunosuppressive polypeptides and nucleic acids
JP5563990B2 (en) 2008-01-03 2014-07-30 ヴェレニウム コーポレイション Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
EP2706122A3 (en) 2008-01-03 2014-06-18 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
BRPI0909611B8 (en) 2008-05-23 2022-12-06 Pioneer Hi Bred Int METHOD OF INCREASE THE TOTAL FATTY ACID CONTENT OF AN OILSEED CELL, RECOMBINANT NUCLEIC ACID, CONSTRUCTION OF RECOMBINANT DNA AND METHOD OF PRODUCTION OF AN OILSEED
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
MY156333A (en) 2008-09-26 2016-02-15 Tocagen Inc Gene therapy vectors and cytosine deaminases
WO2010135588A2 (en) 2009-05-21 2010-11-25 Verenium Corporation Phytases, nucleic acids encoding them and methods for making and using them
CA2770854A1 (en) 2009-08-20 2011-02-24 Pioneer Hi-Bred International, Inc. Functional expression of shuffled yeast nitrate transporter (ynt1) in maize to improve nitrate uptake under low nitrate environment
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
MX2012007681A (en) 2009-12-31 2013-01-29 Pioneer Hi Bred Int Engineering plant resistance to diseases caused by pathogens.
EP2603591A1 (en) 2010-08-13 2013-06-19 Pioneer Hi-Bred International Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity
US20150184173A1 (en) 2012-05-04 2015-07-02 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
BR112015023272A2 (en) 2013-03-14 2017-07-18 Pioneer Hi Bred Int plant cell, plant, plant explant, transgenic seed, method for producing a plant cell having a heterologous polynucleotide encoding a polypeptide having dicamba decarboxylase activity, method for controlling weeds in a field containing a crop and method for controlling weeds in a field containing a culture
CA2904537A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
EP2971000A4 (en) 2013-03-15 2016-11-23 Pioneer Hi Bred Int PHI-4 POLYPEPTIDES AND METHODS OF USE
BR112016003225B1 (en) 2013-08-16 2022-10-25 Pioneer Hi-Bred International, Inc. PIP-47 POLYPEPTIDE, CHIMERIC PIP-47 POLYPEPTIDE, COMPOSITION, FUSION PROTEIN, METHOD FOR CONTROLLING A PEST INSECT POPULATION, METHOD FOR INHIBITING THE GROWTH OR KILLING A PEST INSECT, DNA CONSTRUCTION, ISOLATED POLYNUCLEOTIDE, EXPRESSION CASSETTE, METHOD OF OBTAINING A TRANSGENIC PLANT AND METHOD TO CONTROL INSECT INFESTATION
BR122021005579B1 (en) 2013-09-13 2022-11-29 Pioneer Hi-Bred International, Inc DNA CONSTRUCTION, METHOD FOR OBTAINING A TRANSGENIC PLANT, FUSION PROTEIN, METHOD FOR CONTROLLING AN INSECT PEST POPULATION, METHOD FOR INHIBITING THE GROWTH OR KILLING AN INSECT PEST
US10480007B2 (en) 2014-02-07 2019-11-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants
CA2939156A1 (en) 2014-02-07 2015-08-13 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US10098943B2 (en) * 2014-09-11 2018-10-16 Vlp Therapeutics, Llc Flavivirus virus like particle
RU2733898C2 (en) 2014-10-16 2020-10-09 Пайонир Хай-Бред Интернэшнл, Инк. Insecticidal proteins and methods of using them
CN107635396B (en) 2015-01-15 2021-12-24 先锋国际良种公司 Insecticidal proteins and methods of use thereof
EP3267796B1 (en) 2015-03-11 2023-08-09 Pioneer Hi-Bred International, Inc. Insecticidal combinations of pip-72 and methods of use
CA2985198A1 (en) 2015-05-19 2016-11-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
ES2926808T3 (en) 2015-08-06 2022-10-28 Pioneer Hi Bred Int Plant-derived insecticidal proteins and methods of their use
EP3390431A1 (en) 2015-12-18 2018-10-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MX387077B (en) 2016-05-04 2025-03-19 Pioneer Hi Bred Int INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE.
AU2017283118B2 (en) * 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3954202A1 (en) 2016-07-01 2022-02-16 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
MX387927B (en) 2016-11-01 2025-03-19 Pioneer Hi Bred Int INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE.
EP3555118B1 (en) 2016-12-14 2021-08-18 Pioneer Hi-Bred International Inc. Insecticidal proteins and methods for their use
MX2019007491A (en) 2016-12-22 2019-09-06 Pioneer Hi Bred Int Insecticidal proteins and methods for their use.
CA3052794A1 (en) 2017-02-08 2018-08-16 Pioneer Hi-Bred International, Inc. Insecticidal combinations of plant derived insecticidal proteins and methods for their use
MX2019013321A (en) 2017-05-11 2020-02-10 Pioneer Hi Bred Int Insecticidal proteins and methods for their use.
CA3092078A1 (en) 2018-03-14 2019-09-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
CN116410286A (en) 2018-03-14 2023-07-11 先锋国际良种公司 Insecticidal proteins from plants and methods of use thereof
JP7662531B2 (en) 2019-03-28 2025-04-15 ダニスコ・ユーエス・インク Engineered antibodies
CA3163708A1 (en) 2020-01-10 2021-07-15 Yi Tang Biosynthetic platform for the production of olivetolic acid and analogues of olivetolic acid
CA3186978A1 (en) 2020-07-14 2022-01-20 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1999023236A1 (en) * 1997-10-31 1999-05-14 Diversa Corporation Method of dna shuffling

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
JPH08510639A (en) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ Encapsulation of conjugates and nucleic acids for enhanced cellular uptake and gene expression and targeting
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
WO1994026787A1 (en) * 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Method for generating cell type specific phage antibody libraries
SE9304060D0 (en) * 1993-12-06 1993-12-06 Bioinvent Int Ab Methods to select specific bacteriophages
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
AU4010395A (en) * 1994-10-27 1996-05-23 Amgen, Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
WO1996023882A1 (en) * 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
JPH11512724A (en) * 1995-09-28 1999-11-02 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Immunization with targeted particulate genes enhances immune response in cell therapy
AU1865297A (en) * 1996-03-08 1997-09-22 University Of Toronto, The Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
US6096548A (en) * 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1999023236A1 (en) * 1997-10-31 1999-05-14 Diversa Corporation Method of dna shuffling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEATHER L. DAVIS ET AL.: "DNA-based immunization", MOLECULAR AND CELL BIOLOGY OF HUMAN GENE THERAPEUTICS, vol. 5, 1995, pages 368 - 387, XP002110405 *
PATTEN P A ET AL: "APPLICATIONS OF DNA SHUFFLING TO PHARMACEUTICALS AND VACCINES", CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 724 - 733, XP002916609, ISSN: 0958-1669 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629170B2 (en) 1997-01-17 2009-12-08 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7579146B2 (en) 1999-01-05 2009-08-25 Trustees Of Boston University Nucleic acid cloning
US7421347B2 (en) 1999-01-19 2008-09-02 Maxygen, Inc. Identifying oligonucleotides for in vitro recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7620502B2 (en) 1999-01-19 2009-11-17 Maxygen, Inc. Methods for identifying sets of oligonucleotides for use in an in vitro recombination procedure
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US7282334B2 (en) 2000-12-12 2007-10-16 Alligator Bioscience, Ab Method for in vitro molecular evolution of protein function
US7563578B2 (en) 2000-12-12 2009-07-21 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Also Published As

Publication number Publication date
AU3291099A (en) 1999-08-30
WO1999041402A3 (en) 1999-11-11
MXPA00007891A (en) 2002-09-18
JP2002503461A (en) 2002-02-05
EP1056842A2 (en) 2000-12-06
MXPA00007889A (en) 2002-09-18
WO1999041368A2 (en) 1999-08-19
AU2674199A (en) 1999-08-30
MXPA00007893A (en) 2002-10-23
WO1999041368A3 (en) 1999-12-16
EP1053312A2 (en) 2000-11-22
JP2002503478A (en) 2002-02-05
WO1999041402A2 (en) 1999-08-19
JP2002507392A (en) 2002-03-12
CA2320626A1 (en) 1999-08-19
EP1053343A2 (en) 2000-11-22
WO1999041369A2 (en) 1999-08-19
CA2320431A1 (en) 1999-08-19
CA2320960A1 (en) 1999-08-19
AU2674299A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
WO1999041369A3 (en) Genetic vaccine vector engineering
WO2000046344A3 (en) Non-stochastic generation of genetic vaccines and enzymes
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
EP2397549A3 (en) Non-stochastic generation of genetic vaccines and enzymes
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2000053744A3 (en) End selection in directed evolution
WO2007024941A3 (en) Polyvalent vaccine
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO1999058658A3 (en) Expression vectors for stimulating an immune response and methods of using the same
WO2005056807A3 (en) Bovine adeno-associated viral (baav) vector and uses thereof
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
WO2002004493A3 (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000071154A3 (en) Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
WO2005007673A3 (en) Immunogenic peptides
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
SI1618128T1 (en) Tuberculosis vaccine with improved efficacy
WO2002019968A3 (en) Genetically engineered co-expression dna vaccines, construction methods and uses thereof
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
GB9922361D0 (en) Generating an immune response to an antigen
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2003053338A3 (en) Novel chimeric rev, tat, and nef antigens
WO1997047271A3 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
WO2002028998A3 (en) Chlamydia pmp proteins, gene sequences and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2320626

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 531550

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2320626

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007891

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 32910/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999932508

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999932508

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999932508

Country of ref document: EP